Clinical Trial Update: 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy [EARLY_Phase 1]

View source ↗

Summary

This early Phase 1 trial evaluated the use of copper-64 labeled DOTA-alendronate PET imaging to locate and characterize breast calcifications in participants sc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Carcinoma
• Calcification

Drugs mentioned

• 64Cu-DOTA-alendronate (copper-64 labeled DOTA-alendronate)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Breast Carcinoma, Calcification | EARLY_Phase 1 | Status: COMPLETED